


## BIIL-260 hydrochloride

|                           |  |
|---------------------------|--|
| <b>Cat. No.:</b>          | HY-114641A   |
| <b>CAS No.:</b>           | 192581-24-1  |
| <b>Molecular Formula:</b> | C <sub>30</sub> H <sub>31</sub> ClN <sub>2</sub> O <sub>3</sub>  |
| <b>Molecular Weight:</b>  | 503.03   |
| <b>Target:</b>            | Leukotriene Receptor   |
| <b>Pathway:</b>           | GPCR/G Protein   |
| <b>Storage:</b>           | 4°C, sealed storage, away from moisture<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (248.49 mM; Need ultrasonic)

| Solvent                   | Mass  | Concentration |           |            |
|---------------------------|-------|---------------|-----------|------------|
|                           |       | 1 mg          | 5 mg      | 10 mg      |
| Preparing Stock Solutions | 1 mM  | 1.9880 mL     | 9.9398 mL | 19.8795 mL |
|                           | 5 mM  | 0.3976 mL     | 1.9880 mL | 3.9759 mL  |
|                           | 10 mM | 0.1988 mL     | 0.9940 mL | 1.9880 mL  |
|                           |       |               |           |            |

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor LTB<sub>4</sub> antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB<sub>4</sub> receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB<sub>4</sub> receptor on isolated human neutrophil cell membranes with K<sub>i</sub> values of 1.7 nM<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

LTB<sub>4</sub>  
1.7 nM (K<sub>i</sub>)

#### In Vitro

BIIL-260 hydrochloride potently inhibits LTB<sub>4</sub>-induced intracellular Ca<sup>2+</sup> release in human neutrophils with IC<sub>50</sub> value of 0.82 nM  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Birke FW, et al. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297(1):458-66.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA